These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1754 related items for PubMed ID: 23243017

  • 1. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2013 Feb 15; 73(4):1340-51. PubMed ID: 23243017
    [Abstract] [Full Text] [Related]

  • 2. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.
    Haematologica; 2015 Dec 15; 100(12):1553-63. PubMed ID: 26452980
    [Abstract] [Full Text] [Related]

  • 3. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 4. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, Hsi ED, Almasan A.
    Cell Death Dis; 2015 Jan 15; 6(1):e1593. PubMed ID: 25590803
    [Abstract] [Full Text] [Related]

  • 5. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S, Dai Y, Pei XY, Grant S.
    Mol Cell Biol; 2009 Dec 15; 29(23):6149-69. PubMed ID: 19805519
    [Abstract] [Full Text] [Related]

  • 6. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S.
    Clin Cancer Res; 2014 Sep 15; 20(18):4849-60. PubMed ID: 25070836
    [Abstract] [Full Text] [Related]

  • 7. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.
    Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S.
    Blood; 2009 Nov 12; 114(20):4507-16. PubMed ID: 19773546
    [Abstract] [Full Text] [Related]

  • 8. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 9. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.
    Leukemia; 2012 Apr 15; 26(4):778-87. PubMed ID: 22064351
    [Abstract] [Full Text] [Related]

  • 10. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2018 Jun 01; 78(11):3075-3086. PubMed ID: 29559471
    [Abstract] [Full Text] [Related]

  • 11. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW.
    Cell Death Differ; 2015 Dec 01; 22(12):2098-106. PubMed ID: 26045046
    [Abstract] [Full Text] [Related]

  • 12. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP, Reynolds CP, Kang MH.
    Clin Cancer Res; 2016 Feb 01; 22(3):621-32. PubMed ID: 26080839
    [Abstract] [Full Text] [Related]

  • 13. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM.
    J Biol Chem; 2011 Mar 18; 286(11):9382-92. PubMed ID: 21148306
    [Abstract] [Full Text] [Related]

  • 14. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
    Mol Cancer Ther; 2017 Jan 18; 16(1):102-115. PubMed ID: 27980105
    [Abstract] [Full Text] [Related]

  • 15. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.
    Cancer Res; 2012 Aug 15; 72(16):4225-37. PubMed ID: 22693249
    [Abstract] [Full Text] [Related]

  • 16. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.
    Mol Cancer Ther; 2012 May 15; 11(5):1122-32. PubMed ID: 22411899
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Blood; 2012 Jun 21; 119(25):6089-98. PubMed ID: 22446485
    [Abstract] [Full Text] [Related]

  • 18. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J, Huang K, O'Neill KL, Pang X, Luo X.
    Cell Death Dis; 2016 Jun 16; 7(6):e2266. PubMed ID: 27310874
    [Abstract] [Full Text] [Related]

  • 19. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
    Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, Rathmell JC.
    Cancer Res; 2011 Aug 01; 71(15):5204-13. PubMed ID: 21670080
    [Abstract] [Full Text] [Related]

  • 20. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S, Sinicrope FA.
    Cancer Res; 2008 Apr 15; 68(8):2944-51. PubMed ID: 18413764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 88.